Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
May be involved in proteolysis through its threonine endopeptidase activity (By similarity).. Additionally we are shipping Protease, serine, 50 Kits (7) and Protease, serine, 50 Proteins (6) and many more products for this protein.
Showing 10 out of 32 products:
findings indicate that BORIS (show CTCFL Antibodies)-induced expression of TSP50 is governed by accessibility and binding of BORIS (show CTCFL Antibodies) to the promoter
TSP50 promotes cell proliferation, at least partially, through activation of the NF-kappaB (show NFKB1 Antibodies) signalling pathway.
results showed that downregulation of TSP50 expression in P19 embryonal carcinoma stem cells not only reduced cell proliferation, colony formation, and migration but also induced cell apoptosis
TSP50 may perform a critical biologic function in mammalian spermatogenesis. It may be a new type of threonine protease whose linear catalytic structure is similar to many serine proteases, except f (show TRH Antibodies)or a Thr (show SIGLEC1 Antibodies)-for-Ser residual catalytic site substitution.
These findings suggested that DNA methylation (show HELLS Antibodies) might regulate the TSP50 and mTSP50 gene expressions in different types of tissues and spermatic cells.
TSP50 promotes the proliferation, migration and invasion of gastric cancer cells involving NF-kappaB (show NFKB1 Antibodies) dependent EMT (show ITK Antibodies) activation. Targeting TSP50 may provide a novel therapeutic strategy for the management of gastric cancer
human epidermal growth factor receptor (show EGFR Antibodies) 2 (HER-2 (show ERBB2 Antibodies)) levels, were correlated well with TSP50/p-Samd2 (show SARM1 Antibodies)/3 and TSP50/p27 (show PAK2 Antibodies) expression status. Thus, our studies revealed a novel regulatory mechanism underlying TSP50-induced cell proliferation and provided a new favorable intervention target for the treatment of breast cancer
In patients with Colon cancer, the expression of TSP50 gene was associated with a poor prognosis.
TSP50 plays a significant role in NSCLC cell proliferation and may act as a novel oncogene (show RAB1A Antibodies) in the development and progression of NSCLC.
Results suggest that 7P3A, which consists of 70 % 25-methoxyl-dammarane-3beta, 12beta, 20-triol and 30 % artemisinin, exhibits anti-cancer effects, in part, through downregulation of testes-specific protease 50 (TSP50) expression.
Results show that TSP50 is up-regulated in laryngocarcinoma tumour tissues and its down-regulation inhibits cell proliferation, reduces cell migration and induces cell apoptosis of laryngocarcinoma in NF-KB mediated pathway.
we found that some breast cancer diagnosis-associated features such as tumor size, tumor grade, estrogen receptors (ER) and progesterone receptors (PR) levels, were correlated well with TSP50/p65 (show GORASP1 Antibodies) and TSP50/MMP9 (show MMP9 Antibodies) expression status
TSP50's threonine protease activity is crucial for its effects on tumor formation.
The mutations in the catalytic triad of TSP50 could significantly depressed TSP50-mediated cell proliferation and tumor formation.
High TSP50 expression is associated with laryngocarcinoma.
May be involved in proteolysis through its threonine endopeptidase activity (By similarity).
probable threonine protease PRSS50
, serine protease 50
, testes-specific protease 50
, testis-specific protease-like protein 50
, cancer/testis antigen 20
, testes specific protease 50